Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Breast

• Publication date

  2007-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.BREAST.2007.01.005PMID 17314047
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies.

  2007cited by this paper
• Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer

  2006cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer.

  2005cited by this paper
• Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.

  2005cited by this paper
• The role of BRCA1 in the cellular response to chemotherapy.

  2004cited by this paper

• Modulation of expression of heat shock proteins and apoptosis by Flueggea leucopyrus (Willd) decoction in three breast cancer phenotypes

  2015cites this paper
• Characterization of lovastatin-docosahexaenoate anticancer properties against breast cancer cells.

  2014cites this paper
• A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone

  2011cites this paper
• A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays

  2009cites this paper
• Metformin induces unique biological and molecular responses in triple negative breast cancer cells

  2009cites this paper
• Quantitative immunocytochemical profile to predict early outcome of disease in triple-negative breast carcinomas.

  2009cites this paper
• Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

  2008cites this paper
• Potential targeted therapy options in the management of basal cell subtype of breast carcinoma.

  2007cites this paper